[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
October 1956


Author Affiliations

Baltimore; Norristown, Pa.

AMA Arch Intern Med. 1956;98(4):505-509. doi:10.1001/archinte.1956.00250280107014

PROBENECID (Benemid)* has been established as an outstanding uricosuric agent of value in the treatment of chronic gout.† The drug has been shown to control hyperuricemia, to cause the diminution in size and even disappearance of tophi, to cause the resolution and repair of bony destructive lesions of gout, to reduce the incidence of acute attacks of gout in the course of the chronic disease, and to increase the sense of well-being in the gouty subject. Indeed, the drug has been called "the insulin of gout"‡ and has been declared to be "the most significant advance in the treatment of gout in many years."§ Accordingly, the sensitization of a patient to probenecid represents a loss of these potential benefits, especially to the patient who has seen his gout improve even to the point of disappearance of tophi, and it is a loss to which the patient can reconcile himself only